Osteopore (ASX:OSX) reported the early cessation of its AU$18.7 million dental grant clinical-industrial partnership project after a strategic review, according to a Thursday Australian bourse filing.
The decision will allow for a reallocation of resources and align with its near- and mid-term objectives of prioritizing commercialization.
The firm had been looking for opportunities to improve cost center performance while at the same time streamlining expenses.
Its shares rose 10% on market close on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。